CytomX Therapeutics, Inc. (CTMX)
Nasdaq: CTMX · Pharmaceutical Preparations · South San Francisco, CA · filing with the SEC since 2010
Grade4.4
◀ Past 3.4● Present 5.8▶ Future 3.6
Filings
337 filings since 2017 beside 321 insider forms · Accelerated filer · read from EDGAR on Nov 13, 2026Due nextAccelerated filer
10-K
Annual report for the fiscal year ending Dec 31, 2026Accelerated filers have 75 days after the fiscal year ends.
by Mar 16, 2027
10-Q
Quarterly report for the quarter ending Mar 31, 2027Accelerated filers have 40 days after the quarter ends; quarter ends are taken to the month end.
by May 10, 2027
A deadline is the latest date the SEC's rules allow for its filer category. It is not a forecast of the day the company files. Last time, the results release (8-K item 2.02) came 36 days after the quarter ended. The proxy statement was last filed Apr 30, 2026.
Filings a yearinsider forms included
5460635964577159
2026 counts to Nov 13, 2026.
Officer or director change (8-K item 5.02): 6 times in the last 36 months, the newest Jul 27, 2026.Listing warning from its exchange (8-K item 3.01): 1 time in the last 36 months, the newest Feb 26, 2025.SEC letters: 4 in the last 36 months, the newest Aug 14, 2025.
Insider forms (3, 4, 5 and 144) are counted each year but not listed here; the people and their trades are on the Ownership tab.
FiledFormWhat it is, in plain wordsPeriodAsk
Jun 22, 2026
8-K items 5.02, 5.03, 5.07, 9.01
Officer or director change; Charter, bylaw or fiscal-year change; Shareholder vote · Current report
Jun 17, 2026
40 of 337 shown
Every row opens the filing on EDGAR. The plain words are the site's own for each form and each 8-K item; the complete history, insider forms included, is on EDGAR.